Clinical trials can deliver pioneering new treatments for cancer patients – so why are so many people missing out on taking part? And what does the data show us about the impact of Covid-19 on the availability of trials?
The Institute of Cancer Research, London, has collected the latest data on trial recruitment, and commissioned research on the barriers for patients and doctors in being able to access exciting new treatments through trials. The aim was to show how Covid-19 has set back clinical trials for cancer – but also opened up opportunities for speeding up clinical research in the future, to take new treatments to patients more quickly.
Journalists joined the SMC on Zoom to hear from three cancer trial experts on:
Professor Christina Yap, Professor of Clinical Trials Biostatistics at The Institute of Cancer Research, London.
Professor Udai Banerji, Deputy Director of the Drug Development Unit at The Institute of Cancer Research, London
Professor Nick James, Professor of Prostate and Bladder Cancer Research at The Institute of Cancer Research, London, and Chief Investigator of the STAMPEDE prostate cancer trial.